| Old Articles: <Older 8181-8190 Newer> |
|---|
 |
The Motley Fool
January 2, 2012
Sean Williams |
2012 Preview: Aeterna Zentaris Let's look ahead and see what will be driving Aeterna's stock price in 2012.   |
The Motley Fool
December 31, 2011
David Williamson |
2011 Review: Cell Therapeutics After starting the year at a split-adjusted $2.22 a share, Cell Therapeutics stock lost almost 50% of its value by the end of December, closing at $1.16. How did we get here? |
The Motley Fool
December 31, 2011
Brian Orelli |
3 More Stock-Moving Binary Events to Watch in 2012 There are a lot of drugs that will face binary events in 2012 -- here are three to watch. |
The Motley Fool
December 31, 2011
Brian Orelli |
3 Stock-Moving Binary Events to Watch in 2012 Binary events, FDA decisions, and clinical trial results, are the lifeblood -- and death wish -- of the biotech industry. Here are three to watch in 2012. |
The Motley Fool
December 30, 2011
Brian Orelli |
Working Through the Obese To-Do List in 2011 Arena ends the year on an upswing. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look For With Seattle Genetics in 2012 The launch of its new drug Adcetris will be key. |
The Motley Fool
December 29, 2011
Brian Orelli |
Too Early for a New Biotech Orphan? Alexion Pharmaceuticals is profitable with a drug on the market. The next logical step in the progression of a biotech is to buy another company to stock the pipeline. |
The Motley Fool
December 29, 2011
Brian Orelli |
What to Look for From Keryx and Aeterna Zentaris in 2012 The future is uncertain for these pharmaceutical companies. |
The Motley Fool
December 29, 2011
Harsh Chauhan |
Why Medtronic Is On Course for a Happy New Year Right moves make Medtronic a good investment now. |
| <Older 8181-8190 Newer> Return to current articles. |
